Recently, the world was shocked to find out that King Charles was diagnosed with prostate cancer. In the wake of this news, TheGlitz spotlights Sonablate HIFU (High-Intensity Focused Ultrasound) technology, a ground-breaking advancement offering precise and focused ablative energy to patients with prostate conditions. Read on…
Sonablate, a pioneering medical technology company, proudly unveils its latest innovation at the Kokilaben Dhirubhai Ambani Hospital, in Mumbai: Sonablate HIFU (High-Intensity Focused Ultrasound) technology. This ground-breaking advancement is a minimally invasive robotic device offering precise and focused ablative energy to patients with prostate conditions. NovoMed Incorporation Pvt Ltd is the authorised distributor of the Sonablate HIFU Robotic Device in India.
The key benefit of the Sonablate HIFU Technology is the fact, that it is a customizable procedure targeting only the affected prostate issue, thereby reducing the risk of collateral damage to surrounding healthy tissues. Further, it is also a minimally invasive, radiation-free, bloodless ablation with much shorter recovery periods.
Speaking on the occasion Dr Yuvaraja, Head- Robotic Surgery,and Consultant-Surgical Oncology (URO-ONCOLOGY), at Kokilaben Dhirubhai Ambani Hospital, opined, “I have recently started using this technology and have successfully completed five HIFU procedures for prostate cancer in this short time. My experience has been excellent. There are many advantages of this procedure for patients and the surgical team as well. Patients wake up from anaesthesia without any pain from the surgery. They resume ambulation on the same day, just with a urinary catheter. They can be discharged the next day of surgery and the catheter can be removed at home after three days. Therefore, these patients have very quick recovery as compared to those who undergo conventional surgery. Our patients tolerated this procedure better than prostate biopsies. Out of all these five cases, only one patient had complaints of mild urgency during urination. Intra-operatively also the machine was very easy to use and user-friendly. Overall, I had a very good satisfying experience.”
Rajesh Sharma (name changed to protect identity), a patient of Dr Yuvaraja, underwent the procedure in October and was discharged the very next day. Sunil Kumar Verma stated, “Needless to say the procedure, the way I see it, has been good. The hospitalisation period was short. I felt absolutely normal within two days and could even travel abroad for a vacation within two weeks. Most importantly, I am not on any additional medicines now, and leading an active healthy life.”
Dr Yuvaraja averred, “The future of medicine lies in the hands of minimally invasive approaches. Robotic surgery and laparoscopic surgery are the present paradigm shift for the treatment of prostate cancer. However, targeted focal therapies like HIFU are going to take off across the globe as the standard treatment for a wide range of indicated conditions. HIFU is already treating a wide range of medical conditions globally with its proven efficacy in cancers like prostate cancer. Patient satisfaction along with cancer control is the key with HIFU. Further advancements in technologies including multiparametric MRI, high-resolution TRUS, contrast-enhanced ultrasound, elastography, and Doppler for precise lesion targeting will be empowering this modality of treatment and without any doubt, more men with prostate cancer will choose HIFU to have a new lease on life.”
Jay Mehta, Director- Sales, NovoMed Incorporation Pvt Ltd, aptly sums it up by asserting, “We are thrilled to introduce Sonablate HIFU Technology, a game changer in the field of prostate care. This significant advancement in healthcare technology will ensure a highly improved quality of life for patients with prostate conditions.”